Physiologically based pharmacokinetics of molecular imaging nanoparticles for mRNA detection determined in tumor-bearing mice.
Disease detection and management might benefit from external imaging of disease gene mRNAs. Previously we designed molecular imaging nanoparticles (MINs) based on peptide nucleic acids complementary to cancer gene mRNAs. The MINs included contrast agents and analogs of insulin-like growth factor 1 (IGF-1). Analysis of MIN tumor uptake data showed stronger binding in tumors than in surrounding tissues. We hypothesized that MINs with an IGF-1 analog stay in circulation by binding to IGF-binding proteins. To test that hypothesis, we fit the tissue distribution results of several MINs in xenograft-bearing mice to a physiological pharmacokinetics model. Fitting experimental tissue distribution data to model-predicted mass transfer of MINs from blood into organs and tumors converged only when the parameter for MINs bound to circulating IGF-binding proteins was set to 10%-20% of the injected MIN dose. This result suggests that previous mouse imaging trials used more MINs than necessary. This prediction can be tested by a ramp of decreasing doses.
Opitz
Armin W
AW
Department of Chemical Engineering, Center for Molecular and Engineering Thermodynamics, University of Delaware, Newark, Delaware 19716, USA.
Wickstrom
Eric
E
Thakur
Mathew L
ML
Wagner
Norman J
NJ
D000818:Animals; D051379:Mice; D053758:Nanoparticles; D009374:Neoplasms, Experimental / Q000235:genetics*; D010599:Pharmacokinetics; D012333:RNA, Messenger / Q000032:analysis*; D014018:Tissue Distribution
D012333:RNA, Messenger
Ann Emerg Med. 1986 Apr;15(4):390-6
3954170
J Nucl Med. 2007 Oct;48(10):1699-707
17909257
Ann Biomed Eng. 2006 Apr;34(4):618-32
16547609
Growth Horm IGF Res. 2003 Aug;13(4):113-70
12914749
Biotechnol Prog. 1999 May-Jun;15(3):540-55
10356275
J Pharm Sci. 1983 Oct;72(10):1103-27
6358460
Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):435-44
14604834
Eur J Cancer Clin Oncol. 1983 Jul;19(7):1021-9
6684042
MAGMA. 2004 Dec;17(3-6):157-61
15609036
J Pharmacokinet Pharmacodyn. 2003 Jun;30(3):185-219
14571691
Am J Physiol. 1996 Oct;271(4 Pt 1):E649-57
8897852
J Clin Invest. 1986 Dec;78(6):1504-12
2431001
J Nucl Med. 2004 Dec;45(12):2070-82
15585484
Biopolymers. 2008 Dec;89(12):1061-76
18680101
Ann N Y Acad Sci. 2003 Dec;1002:165-88
14751834
J Pharmacokinet Biopharm. 1994 Aug;22(4):259-92
7699583
J Appl Toxicol. 1983 Dec;3(6):310-2
6677653
Cancer Res. 1988 May 15;48(10):2641-58
3282647
Microvasc Res. 1993 May;45(3):269-89
8321142
Circ Res. 1956 Jul;4(4):419-24
13330185
Am J Physiol. 1997 Aug;273(2 Pt 1):E438-47
9277399
Proc Soc Exp Biol Med. 1950 Jul;74(3):644-8
15440918
J Cell Physiol. 1997 Mar;170(3):290-8
9066786
J Cell Physiol. 2007 Feb;210(2):298-308
17044083
Pharm Res. 2001 Aug;18(8):1203-9
11587493
Cancer. 1974 Jan;33(1):103-10
4810083
Ann N Y Acad Sci. 2005 Nov;1059:106-44
16382049
Am J Physiol. 1990 Mar;258(3 Pt 1):G365-9
2316651
Am J Physiol. 1992 Sep;263(3 Pt 2):R728-33
1415664
Gut. 2002 Apr;50(4):507-12
11889071
Lab Anim. 2002 Jan;36(1):1-19
11833526
Physiol Rev. 1990 Jul;70(3):591-614
1694588
Am J Physiol Gastrointest Liver Physiol. 2005 Jun;288(6):G1328-38
15637179
Curr Top Dev Biol. 2005;70:1-33
16338335
J Clin Endocrinol Metab. 1989 Mar;68(3):535-41
2563734
Lab Anim. 2002 Oct;36(4):411-9
12396284
J Pharmacokinet Biopharm. 1997 Jun;25(3):277-312
9474530
Proc R Soc Lond B Biol Sci. 1965 Jul 27;162(989):502-16
4378461
Lab Anim Sci. 1972 Oct;22(5):712-20
4343328
Bioconjug Chem. 2005 Jan-Feb;16(1):70-9
15656577
J Endocrinol. 1999 Sep;162(3):361-9
10467227
Methods Inf Med. 1994 Dec;33(5):514-21
7869950
Antisense Nucleic Acid Drug Dev. 2001 Feb;11(1):15-27
11258618
Cancer Res. 1989 Jul 15;49(14):3759-64
2736517
Toxicol Appl Pharmacol. 1990 Nov;106(2):295-310
2256118
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
17237035
Cancer Res. 1994 Mar 15;54(6):1517-28
8137258
Cancer Biol Ther. 2007 Jun;6(6):948-56
17611392
J Pharm Sci. 2000 Jan;89(1):115-27
10664544